About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The company is developing several product candidates in neurology and psychiatry to address large market opportunities in epilepsy and ADHD including ADHD patients with impulsive aggression. These product candidates include Trokendi XR (extended-release topiramate), formerly known as SPN-538, and SPN-804 (extended-release oxcarbazepine) for epilepsy, SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information, but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company's ability to achieve profitability; the Company's ability to raise sufficient capital to implement its corporate strategy; the implementation of the Company's corporate strategy; the Company's future financial performance and projected expenditures; the Company's ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company's product research and development activities, including the timing and progress of the Company's clinical trials, and projected expenditures; the Company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company's product candidates; the Company's respective PDUFA dates for product candidates; the Company's ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others; the Company's expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company's product candidates; the accuracy of the Company's estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company's ability to increase its manufacturing capabilities for its product candidates; the Company's projected markets and growth in markets; the Company's product formulations and patient needs and potential funding sources; the Company's staffing needs; and other risk factors set forth from time to time in the Company's SEC filings made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.
|SUPERNUS PHARMACEUTICS, INC.|
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|December, 31||June 30,|
|Cash, cash equivalents and marketable securities||$ 48,544||$ 76,392|
|Other current assets||855||1,413|
|Total current assets||49,399||77,805|
|Property and equipment, net||1,310||1,146|
|Deferred financing costs||2,054||161|
|Other long-term assets||967||853|
|Accounts payable and accrued expenses||$ 11,625||$ 10,510|
|Secured notes payable, current||6,775||10,747|
|Other current liabilities||370||624|
|Total current liabilities||18,770||21,881|
|Secured notes payable, long-term||22,711||17,061|
|Total Stockholders' Equity||9,443||37,980|
|Total Liabilities & Stockholders Equity||$ 53,730||$ 79,965|
|SUPERNUS PHARMACEUTICS, INC.|
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS|
|(in thousands, except per share data)|
|Three months ended||Six months ended|
|June 30, 2011||June 30, 2012||June 30, 2011||June 30, 2012|
|Total revenues||$ 750||$ 91||$ 750||$ 299|
|Research and development||7,251||4,703||14,702||10,061|
|General and administrative||1,895||4,645||3,642||7,374|
|Total operating expenses||9,146||9,348||18,344||17,435|
|Other income (expense):|
|Net loss from continuing operations||(8,940)||(10,013)||(18,655)||(19,288)|
|Net loss||$ (7,377)||$ (10,013)||$ (18,426)||$ (19,288)|
|Cumulative Dividends on Preferred Stock||$ (858)||$ (286)||$ (1,715)||$ (1,143)|
|Net loss attributable to common shareholders||$ (8,235)||$ (10,299)||$ (20,141)||$ (20,431)|
|Net loss per share - basic & diluted||$ (5.17)||$ (0.61)||$ (12.64)||$ (2.21)|
|Weighted average number of shares outstanding (post-split)||1,594,246||16,817,841||1,593,508||9,247,142|
CONTACT: Jack Khattar, President & CEO Gregory S. Patrick, Vice President and CFO Supernus Pharmaceuticals, Inc. Tel: (301) 838-2591
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV